Organoid Therapeutics is pioneering the development of organoid-based technologies aimed at addressing hormone deficiencies and enhancing drug discovery and toxicology testing. Their innovative approach utilizes lab-grown artificial organs, specifically designed to provide alternatives for patients suffering from end-stage glandular organ disease. The company employs a combination of human organoid technologies, genetic engineering, next-generation biomaterials, and advanced robotics to manufacture functional glandular organs. A key aspect of their technology is the use of induced pluripotent stem cells (iPSCs), which are reprogrammed from skin or blood cells to generate insulin-producing pancreatic islet cells. This self-regulating system is designed to be universally compatible, eliminating the need for immunosuppressants and reducing the risk of immunorejection.

In addition to their organoid technologies, Organoid Therapeutics focuses on creating a functional vascular network within their organoids, which is crucial for the survival and integration of transplanted cells. By incorporating micro-vessel fragments into a 3D coculture, they facilitate the development of a vascular system that can seamlessly connect with the host's vasculature post-implantation. Their genetic engineering strategy employs CRISPR-Cas9 technology to modify HLA molecules, allowing for the establishment of universally compatible cell banks. This innovative approach not only mitigates the challenges of immunorejection but also enhances the scalability of organoid production through robotic automation, making it a promising solution for the growing demand for organ transplants.

United States

Organoid Therapeutics is developing organoid-based technologies to correct hormone deficiencies in patients and streamline drug discovery and toxicology testing in the lab.

Organoid Therapeutics

Company Details